Exploris Health AG

What Exploris Health AG does

Exploris Health AG is a Swiss healthcare technology company headquartered in Wallisellen, Zürich, founded in 2018 with approximately 12 employees. The company develops AI-based diagnostic and therapy solutions, anchored by Cardio Explorer, a non-invasive IVDR Class B certified medical device that uses a proprietary multi-marker AI algorithm to assess the clinical likelihood of obstructive coronary artery disease (CAD) by combining blood biomarkers (including Hs-troponin T, cholesterol, and liver function markers), ECG data, symptoms, and clinical risk factors. The algorithm is validated in three peer-reviewed studies with over 2,000 patients and achieves a diagnostic accuracy (AUC) of 0.87, comparable to cardiac CT and MRI, with NPV greater than 95% at 15% threshold. The company also markets Heart Failure Explorer, a personalized therapy solution for heart failure self-management, and an 'AI as a service' predictive modeling platform.

Exploris Health operates a per-test revenue model in which Cardio Explorer is delivered at medical partner locations (hospitals, clinics, prevention centers) at an average of CHF 350 per screening in Switzerland, with reimbursement from Swiss supplementary insurance (Helsana Primeo covers 90% up to CHF 5,000/year; CSS Health Account). Go-to-market combines enterprise field sales to hospitals, channel partners (Medbase, Alfadiag, Sana Praevention) for prevention and regional distribution, and insurance-led demand generation. The company has clinical validation partnerships with University Hospital Basel, Maastricht UMC+, and Heart and Vascular Center Bad Bevensen, and serves customers including Medcare Hospitals (UAE), Sana Praevention (Germany), and CSS/Helsana (Switzerland).

The company has secured CE marking, UK certification, ISO 13485:2016 from BSI, and EQUAL CARE certification, and operates in Switzerland, Germany, the Netherlands, the UK, and the UAE. A September 2025 global cooperation with Roche provides worldwide distribution access to Cardio Explorer, marking a pivotal commercial inflection point. The company is private, founder-led under CEO Peter Ruff, and has expanded its Board of Directors in March 2025 in preparation for international scale-up.

Name

Exploris Health AG

Legal name

Exploris Health AG

Website

https://en.explorishealth.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Exploris Health AG is a Swiss AI-diagnostics company offering Cardio Explorer, a CE/IVDR-certified AI-based non-invasive test for obstructive coronary artery disease, serving hospitals, clinicians, insurers, and prevention centers across DACH, Benelux, UK, and the UAE.

Ownership category

akta.pro rank

Product category

AI-based Cardiac Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)

akta.pro secondary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• AI diagnostics
• Cardiac diagnostics
• Medical device software
• Heart failure therapy
• Blood biomarker analysis

Headquarters

HQ city

Wallisellen

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Cardio Explorer Diagnostic Test: Revenue generated from per-test fees for the Cardio Explorer AI-based diagnostic test for coronary heart disease. Tests are performed at medical partner locations (hospitals, clinics, practices). Average cost in Switzerland is CHF 350 per screening. Insurance reimbursement available through partners like Helsana (covers 90% for Primeo customers) and CSS Health Account.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

Exploris Health AG develops and sells AI-based diagnostic and therapy solutions for cardiovascular care. Its flagship product Cardio Explorer is a non-invasive, IVDR Class B certified test that uses an AI-enhanced algorithm to assess the clinical likelihood of obstructive coronary artery disease by analyzing blood biomarkers, ECG data, symptoms, and clinical risk factors. The company also offers Heart Failure Explorer for personalized heart-failure therapy and an AI-as-a-service Data Science and Predictive Modeling platform for healthcare applications.

Product overview

Exploris Health AG offers an AI-powered diagnostic platform centered around two main products: Cardio Explorer (a non-invasive IVDD-cleared test for obstructive coronary artery disease validated in 3 clinical studies with 2,000+ patients) and Heart Failure Explorer (personalized therapy for heart failure). The company also provides AI as a service through its Data Science & Predictive Modeling platform. The Cardio Explorer achieves diagnostic accuracy (AUC 0.87) comparable to imaging procedures by analyzing blood biomarkers, ECG data, symptoms, and clinical risk factors. The company operates as a provider of IVDR Class B AI-based diagnostic tests with ISO 13485 certification.

Differentiator

Problem solved

Functional benefit

Brands

• Cardio Explorer: AI-based non-invasive diagnostic test for coronary artery disease (CAD) that calculates pre-test probability using blood biomarkers, ECG data, symptoms, and clinical risk factors. CE and UK certified medical device.
• Heart Failure Explorer
• AI X Plattform

Products and services

• Cardio Explorer Non-invasive IVDR Class B certified AI-based diagnostic test for obstructive coronary artery disease. Uses an AI-enhanced algorithm to assess clinical likelihood by analyzing blood biomarkers (including Hs-troponin T, cholesterol, liver function markers), ECG data, symptoms, and clinical risk factors. Achieves diagnostic accuracy (AUC) of 0.87 comparable to imaging procedures. Validated in 3 peer-reviewed clinical studies with over 2,000 patients. CE marked for EU and UK. For hospitals, cardiologists, GPs, and screening centers.
• Cardio Explorer v2.0 Updated version 2.0 of the Cardio Explorer test with refined instructions for use and IVDR Class B certification as an AI-based diagnostic test for obstructive coronary artery disease.
• Heart Failure Explorer AI-based personalized therapy solution for heart failure that enables patient self-treatment and optimizes therapy management. Under development as further AI application beyond Cardio Explorer.
• AI as a Service - Data Science and Predictive Modeling Platform Technology platform enabling rapid analysis of complex data structures and development of new AI-based diagnostic and healthcare applications. For healthcare organizations needing custom AI and predictive modeling capabilities.

Quantifiable outcome

• 96 out of 100 patients correctly identified as not having obstructive CAD at 15% threshold (NPV >95%)
• +3 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

17 partnerships are on record, tiered minor, core and major.

• Graduate Consulting Club (GCC) at ETH ZurichminorStrategic or Co-development Partner · 28 May 2026Strategic growth project for Cardio Explorer market entry strategy for hospital sector. GCC team from ETH Zurich, University of Basel, and University of Zurich provided analytical precision and healthcare expertise.
• Post Sanela Health AGcoreStrategic or Co-development Partner · 18 November 2025Integration of Cardio Explorer into the Swiss Electronic Patient Record (EPD). Enables automatic and secure storage of examination results with direct access for patients and healthcare professionals. Partnership part of Sanela master community for secure healthcare networking.
• Medcare Hospitals & Medical CentrescoreStrategic or Co-development Partner · 23 September 2025Dubai-based hospital system using Cardio Explorer for early detection of coronary heart disease. Dr. Brajesh Mittal, Head of Cardiology at Medcare Hospital Al Safa, called it a 'real game changer for early intervention'.
• AlfadiagcoreChannel Partner/ Reseller/ Distributor · 23 September 2025Sales partner in UAE region responsible for distribution and sales support for Medcare Hospitals partnership.
• Swiss InsurTech HubmajorStrategic or Co-development Partner · 9 September 2025Active member of Swiss InsurTech Hub network. Participation in Digital Health Summit 2025 at Swiss Re in Zurich with other innovators in personalized healthcare.
• DayOne Accelerator ProgrammajorStrategic or Co-development Partner · 30 August 2024Alumni of DayOne Health 4.0 Accelerator Cohort 2024. Presented at DayOne Innovation Showcase hosted by Roche in Basel alongside influential startup founders and pharmaceutical executives.
• 5-HT Chemistry & HealthminorStrategic or Co-development Partner · 23 April 2024Membership in platform connecting global players and hidden champions from chemical and healthcare sectors with innovative startups. Focus on networking, cooperation, and co-development with additional focus on sustainability.
• Sana PraeventionmajorChannel Partner/ Reseller/ Distributor · 1 October 2023Prevention services provider offering Cardio Explorer health check-ups at Munich and Frankfurt locations. Part of Sana Kliniken AG, one of largest healthcare providers in German-speaking region.
• CSS InsurancecoreChannel Partner/ Reseller/ Distributor · 26 September 2023Cardio Explorer included in CSS 'Health Account' reimbursement package. Policyholders with Health Account supplementary insurance can receive coverage for Cardio Explorer test.
• HelsanacoreChannel Partner/ Reseller/ Distributor · 23 November 2022Cardio Explorer test reimbursed through Helsana Primeo supplementary insurance. Primeo customers covered at 90% of costs up to CHF 5,000 per calendar year. Test available during initial examination at family doctor.
• Heart-Brain AlliancemajorStrategic or Co-development PartnerAlliance of leading healthcare players including Novartis, Abbott, Novo Nordisk, AstraZeneca, Sanofi-Aventis, Siemens, and health insurers AOK. Goal: reduce cardiovascular events in Germany by 30% by 2030 through awareness, prevention, and optimized patient pathways.
• MicrosoftmajorTechnology or IntegrationTechnology partner. CEO Microsoft Germany Marianne Janik praised Exploris' eDiagnostic Services and team's collaboration with senior physicians at leading hospitals.
• Boehringer IngelheimmajorStrategic or Co-development PartnerPharmaceutical partner supporting cardiovascular disease initiatives.
• University Hospital BaselcoreImplementation/ SI/ Consulting PartnerClinical validation partner; Prof. Michael Zellweger serves on Cardio Explorer medical advisory board as Head of Non-Invasive Cardiology.
• Maastricht University Medical CentrecoreImplementation/ SI/ Consulting PartnerClinical validation partner; led CVC Study with 696 patients. Prof. Hans-Peter Brunner-La Rocca serves on Cardio Explorer medical advisory board.
• Heart and Vascular Center Bad Bevensen (HGZ)coreImplementation/ SI/ Consulting PartnerClinical validation partner; Prof. Bjoern Andrew Remppis contributed to Cardio Explorer publications.
• MedbasemajorChannel Partner/ Reseller/ DistributorHealthcare provider partner offering Cardio Explorer campaigns.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• GE Healthcare: GE Healthcare is a broad incumbent in cardiac imaging (CT, MRI, ultrasound) and integrates AI tools for CAD assessment into existing installed bases. Comparable because Exploris's Cardio Explorer positions as a non-invasive, low-cost alternative to GE's imaging-based CAD diagnostic pathways.
• Tempus AI: Tempus AI operates AI-driven precision medicine platforms spanning oncology and cardiology, including cardiovascular risk prediction. Comparable to Exploris as a broader AI diagnostics platform applying predictive analytics to clinical decision support in cardiology.
• Siemens Healthineers: Siemens Healthineers sells cardiac CT, MRI, and angiography systems and is embedding AI decision support. Comparable as a broad incumbent whose AI-enhanced imaging workflow competes with Exploris's biomarker-based non-invasive CAD pre-test.
• Nanox AI (formerly Zebra Medical Vision): Nanox AI provides AI-powered imaging analytics across multiple disease areas including cardiology. Comparable to Exploris as a vendor of AI-based clinical decision support for cardiovascular assessment in hospital settings.

Direct peers

• HeartFlow: HeartFlow provides non-invasive FFR-CT analysis to diagnose coronary artery disease and guide treatment decisions. It is the most direct competitor to Cardio Explorer because both companies target CAD triage to reduce unnecessary invasive catheterizations, using AI-based computational analysis of clinical data — HeartFlow from imaging, Exploris from blood biomarkers and ECG.
• Cleerly Health: Cleerly applies AI to cardiac CT angiography to quantify plaque and identify coronary artery disease. It is a directly comparable AI-CAD diagnostic company competing for the same cardiology pre-test workflow that Cardio Explorer targets.

Emerging players

• AliveCor (KardiaMobile): AliveCor develops AI-driven ECG/ECG-based cardiac diagnostics, including KardiaMobile devices and remote monitoring. Comparable to Exploris in using ECG signals and AI for cardiac risk assessment, but AliveCor is positioned more toward consumer/ambulatory ECG monitoring while Exploris focuses on blood-biomarker-ECG combined CAD pre-test probability.
• Elucid Bioimaging: Elucid provides AI-based cardiovascular imaging analysis for plaque characterization and risk assessment. Comparable as an AI-CAD diagnostic company using validated algorithms to support clinical decision-making in cardiology.
• Caristo Diagnostics: Caristo's CaRi-Heart technology uses AI applied to routine coronary CT angiography to quantify cardiovascular risk. It is comparable as an AI-driven CAD risk-stratification tool with a similar evidence-based, guideline-aligned commercial approach.
• Ultromics: Ultromics provides AI-powered echocardiography analysis for cardiac disease detection. Comparable as a UK/EU-headquartered AI cardiology diagnostics company building evidence-based, regulatory-cleared diagnostic algorithms competing for similar cardiology decision support budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exploris-health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exploris Health AG